spacer
home > ebr > autumn 2009 > investigating interactions
PUBLICATIONS
European Biopharmaceutical Review

Investigating Interactions

 

As a result of scientific efforts over the last few decades, the Protein Data Bank (PDB) library now contains descriptions of more than 48,000 high-resolution biomolecular structures (1). In addition, characterisation data for more than 38,000 of the estimated 300,000 protein-protein interactions in humans has been collected (2). This information is critical to our understanding of interactions between proteins and in the investigation of the effects of these interactions, from academic research to drug discovery and development. Based on the report by Prasad et al, it can be calculated that only around six per cent of the identified interactions have been confirmed in vivo and with the use of several in vitro techniques (2). Thus, although a significant number of interactions are already well-characterised, there is still a need for additional experimental verification.

As well as the need for investigation of protein structure-function relationships and the mapping of the interactome to increase our biological understanding, there is also a growing demand from regulatory authorities to employ orthogonal approaches to biotherapeutic discovery and development. Complementary methods are needed to enable researchers to validate and verify interaction data, and to make confident conclusions and decisions in the drug development process.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Thomas Lundbäck is a Senior Project Manager at GE Healthcare, Life Sciences. He recently joined GE Healthcare from Biovitrum, where he held the positions of project leader and principal scientist, implementing different biophysical techniques. Thomas has a PhD in biophysical chemistry from the Karolinska Institute in Stockholm, Sweden. He is also a member of the Industrial Research Committee at the Royal Swedish Academy of Engineering Sciences (IVA), which represents research areas of future strategic interest for Swedish industry.
spacer
Thomas Lundbäck
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Jackson ImmunoResearch Announces New Range of Antibodies for Serology and Diagnostics Market

West Grove, PA – 02 August 2022: Jackson ImmunoResearch, a manufacturer of secondary antibodies and immunoreagents for the life science market, announces a new addition to its range of products for scientists developing immunoassays for the serology and diagnostics markets. JIR Mouse Monoclonal Anti-Human IgE antibodies are the latest addition to our suite of products suitable for diagnostics research and development.
More info >>

White Papers

Pharmaceuticals and Healthcare Products

Turkish Cargo

Pharmaceuticals are requiring safe and reliable transportation for being highly temperature sensitive products. Thosepharmaceuticals are; diagnostics, vaccines drugs, sera, plasma, protein clinical trials, biotechnological material, pills and all kind of medicines. Turkish Cargo transports all kind of pharmaceuticals, and has been carrying out its operations of transporting and storing drugs and temperature-sensitive medical supplies successfully and with the experience of 80 years; since 1936.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement